Patent intelligence · US
US 11077101
Compounds and methods of use
Compounds and methods of use
Patent details — US 11077101
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 3, 2021
- Expiration
- Jul 29, 2041
- Applicant
- Tango Therapeutics, Inc.
- Claims
- 43
- CPC classes
- A61K, A61K31/4725, A61K31/496, A61K31/5377
Quick answer
US 11077101 (Compounds and methods of use) is held by Tango Therapeutics, Inc.. Status: granted. Granted Aug 3, 2021. Expires Jul 29, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tango Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 43
- CPC classes
- A61K, A61K31/4725, A61K31/496, A61K31/5377, A61K31/5386
More from Tango Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12403137
Compounds and methods of use
granted -
US 12304907
Compounds and methods of use
granted -
US 12264154
Compounds and methods of use
granted -
US 12043607
HDAC inhibitors and therapeutic use thereof
granted -
US 11999727
Compounds and methods of use
granted -
US 11986471
Compounds and methods of use
granted -
US 11492350
Compounds and methods of use
granted
Frequently asked questions
What is US patent 11077101?
US 11077101 (Compounds and methods of use) is held by Tango Therapeutics, Inc.. Status: granted. Granted Aug 3, 2021. Expires Jul 29, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11077101?
Tango Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 11077101 expire?
Our index shows an expiration date of Jul 29, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.